Abstract 1065: Mitosis in circulating tumor cells correlates with highly aggressive disease in metastatic breast cancer

Key Points

• To evaluate the prognostic value of mitotic circulating tumor cells (CTCs) in metastatic breast cancer and their impact on treatment outcomes.
• Collected peripheral blood samples from 138 metastatic breast cancer patients before new systemic therapies.
• Isolated CTCs using CellSieve microfilters and performed fluorescent staining for characterization.
• Categorized CTCs based on the presence of mitotic CTCs and evaluated associations with progression-free survival and overall survival over two years.
• Conducted multivariate analyses to assess therapy efficacy across different treatment types.
• Patients with CTCs had poorer outcomes compared to those without CTCs.
• Patients with mitotic CTCs exhibited the worst survival outcomes.
• No CTCs or non-mitotic CTCs had similar progression-free survival and overall survival in some treatments.
• Patients without CTCs on hormone therapy showed better progression-free survival, while mitotic CTCs had improved overall survival with targeted therapy.

Abstract